CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on February 7, 2007
Clin J Am Soc Nephrol 2: 326-333, 2007
© 2007 American Society of Nephrology
doi: 10.2215/CJN.03751106
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.03751106v1
2/2/326    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letavernier, E.
Right arrow Articles by Legendre, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letavernier, E.
Right arrow Articles by Legendre, C.
Related Collections
Right arrowRelated Article

Transplantation

High Sirolimus Levels May Induce Focal Segmental Glomerulosclerosis De Novo

Emmanuel Letavernier*, Patrick Bruneval{dagger}, Chantal Mandet{dagger}, Jean-Paul Duong Van Huyen{dagger}, Marie-Noëlle Péraldi{ddagger}, Imed Helal*, Laure-Hélène Noël§, and Christophe Legendre*

* Service de Transplantation Adulte, Hôpital Necker, {dagger} Unité INSERM U652, {ddagger} Service de Néphrologie et Transplantation, Hôpital Saint-Louis, and § Unité de pathologie rénale INSERM U507, Paris, France

Address correspondence to: Prof. Christophe Legendre, Service de Transplantation Adulte Hôpital Necker, 149 rue de Sèvres 75743 Paris, France, Phone: +33-1-44-49-54-32; Fax: +33-1-44-49-54-30; E-mail: christophe.legendre{at}nck.ap-hop-paris.fr


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 Disclosures
 References
 
Sirolimus has been associated with high-range proteinuria when used in replacement of calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy (CAN). Primary FSGS was demonstrated previously in some such patients, but the coexistence of CAN lesions made the interpretation uneasy. However, nephrotic syndrome and FSGS were observed recently in three patients who received sirolimus de novo, without medical history of primary FSGS or CAN. Markers of podocyte differentiation were studied in kidney biopsies of the three patients who received sirolimus de novo and of five patients who switched to sirolimus. All patients developed FSGS lesions of classic type (not otherwise specified), but only switched patients exhibited advanced sclerotic lesions. Immunohistochemistry showed that some podocytes in FSGS lesions had absent or diminished expression of the podocyte-specific epitopes synaptopodin and p57, reflecting dedifferentiation, and had acquired expression of cytokeratin and PAX2, reflecting a immature fetal phenotype. Such a pattern of epitope expression provides evidence for podocyte dysregulation. Moreover, a decrease in vascular endothelial growth factor expression was observed in some glomeruli. In conclusion, sirolimus induces FSGS that is responsible for proteinuria in some transplant patients.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Conclusion
 Disclosures
 References
 
The supposed absence of nephrotoxicity that is inherent in sirolimus, coupled with immunosuppressive properties, makes sirolimus an alternative to calcineurin inhibitors (CNI) in renal transplantation. Switching from CNI to sirolimus when chronic allograft nephropathy (CAN) is suspected has become a frequent practice (1–6) but may be complicated by the development of proteinuria and nephrotic syndrome. The increase in the level of proteinuria is predominantly encountered in patients with severe CAN lesions, suggesting that CNI withdrawal might reveal underlying glomerular disease and take part in the development of proteinuria. Nevertheless, in some patients, FSGS may appear in the short term after sirolimus therapy (1).

In this study, we describe the first cases of patients who were treated de novo with sirolimus and developed FSGS lesions in the renal transplant, without any medical history of FSGS in their native kidneys. In addition, we report five cases of patients who developed FSGS after conversion from CNI to sirolimus. These patients offered the occasion to study the early events that characterize this glomerulopathy and allowed immunohistochemical phenotypic identification of glomerular epithelial cells. Some of them were found to undergo phenotypic changes that suggested podocyte dysregulation, providing evidence for an active process that leads to glomerular lesions.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Conclusion
 Disclosures
 References
 
Clinical Data
Since 1997, at least 263 renal transplant recipients have received sirolimus either de novo (n = 76) or after conversion from CNI (cyclosporine or tacrolimus; n = 187) at the Necker and Saint-Louis hospitals in Paris. In this study, we include eight patients who met the following criteria: (1) development of biopsy-proven FSGS lesions during sirolimus treatment; (2) absence of primary FSGS; and (3) for switched patients, (a) proteinuria <0.5 g/24 h before the conversion from CNI to sirolimus, (b) absence of FSGS lesions on renal biopsy performed <3 mo before conversion, and (c) CNI/sirolimus overlap that did not exceed 4 wk.

The clinical characteristics and baseline immunosuppression of the eight patients are detailed in Table 1. Patients 1 to 3 received sirolimus de novo, from the first day of the graft, and patients 4 to 8 received sirolimus after a conversion from CNI. The indication for switching from CNI to sirolimus was the presence of CAN lesions on routine biopsy. We identified a fourth de novo patient with nephrotic-range proteinuria and typical FSGS lesions, but the diagnosis was made retrospectively in a nephrectomy. This case therefore was excluded.


View this table:
[in this window]
[in a new window]

  		Table 1. Patient findingsa

 
In both centers, dosages of sirolimus were usually adjusted to achieve serum levels of 10 to 15 ng/ml. We calculated the mean residual sirolimus serum level during the months that preceded the biopsy. Proteinuria was measured by 24-h urine collection. Patients neither were hypertensive nor received angiotensin-converting enzyme inhibitors before biopsy, and no episode of acute vascular rejection was recorded. Patients did not exhibit anti-HLA antibodies. Graft biopsies were performed on the day of the transplantation in all de novo patients. They displayed only mild lesions according to the Banff classification: "cv1" lesions in patient 2 and "ah1, cv1" lesions in patient 3.

All of the biopsies analyzed herein were performed while patients were receiving sirolimus. A biopsy that was performed in a tacrolimus-treated patient who developed typical FSGS lesions was used as control for vascular endothelial growth factor (VEGF) expression in glomeruli. This patient received a transplant because of nephroangiosclerosis and never received sirolimus.

Renal Biopsies
The renal biopsies were fixed in alcoholic Bouin’s solution and embedded in paraffin for histology and immunohistochemistry. Multiple sections were stained with Masson’s trichrome, periodic acid-Schiff, or silver staining for histopathology. Using immunohistochemistry, podocytes were characterized using an anti-synaptopodin mAb, clone G1D4 (Biogen and Biotechnik, Heidelberg, Germany) and an anti-CKI p57 C-20 polyclonal antibody and an anti-human VEGF mAb, clone C1 (all from Santa Cruz Biotechnology, Santa Cruz, CA). Cytokeratin was labeled using C2562 mAb cocktail (Sigma Aldrich, Saint Quentin Fallavier, France) directed against nine cytokeratin types. Normal adult podocytes are not labeled by C2562 mAb, because fetal podocytes lose cytokeratin expression from the capillary loop stage onward. PAX2 was characterized by an anti-PAX2 polyclonal antibody (Zymed, San Francisco, CA). Normal adult podocytes do not express PAX2 because it disappears from podocytes at the point where the S-shaped bodies transform into the capillary loop stage. Immunohistochemistry procedures were performed as described previously (7,8). FSGS lesions were analyzed according to the recently proposed pathologic classification (9,10).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Conclusion
 Disclosures
 References
 
Clinical Evolution
The evolution of proteinuria and renal function, assessed by serum creatinine level, is detailed in Figure 1 for patients 1 to 3 (de novo sirolimus) and in Figure 2 for patients 4 to 8 (switched patients), providing evidence for a severe and progressive increase in urinary protein excretion rate. In the de novo group, all patients exhibited nephrotic-range proteinuria (maximum from 6.8 to 13.24 g/24 h). In the switched group, mean proteinuria increased from 0.28 ± 0.14 g/24 h before conversion to 2.54 ± 0.99 g/24 h after (n = 5; P = 0.0068, bilateral paired t test). We observed that mean sirolimus trough levels were markedly superior to those currently recommended (Table 1). All de novo patients and two of the switched group were changed from sirolimus to tacrolimus in view of increased proteinuria and FSGS lesions on biopsies, leading to a decrease in proteinuria. No patient was switched back to sirolimus.


Figure 1
View larger version (18K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Proteinuria and renal function in de novo patients. Urinary protein excretion (black lines), serum creatinine level (gray lines), and sirolimus trough levels (bars) are shown for patients 1 to 3, who received sirolimus de novo. Time after renal transplantation is expressed in months (mo). Dotted lines correspond to the time after sirolimus withdrawal, and time of conversion to tacrolimus is indicated by an arrow.

 

Figure 2
View larger version (18K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 2. Proteinuria and renal function in switched patients. Mean urinary protein excretion (black line), mean serum creatinine level (gray line), and mean sirolimus trough level (bar) are shown for patients 4 to 8 before and 3 to 6 mo after a switch from CNI to sirolimus. Error bars correspond to SEM.

 
Renal Biopsies
The indications for biopsy and the histologic data are detailed in Tables 2 and 3. FSGS lesions involved only a few glomeruli (Table 2). They belonged to the classic type (not otherwise specified) variant in all patients but seemed really recent in de novo patients because scar lesions were uncommon, unlike in switched patients, whose lesions were sclerotic (Figure 3). Immunohistochemistry study was incomplete because in some biopsies, previous histologic analysis had exhausted the blocks, especially in patients 3 and 6. Furthermore, FSGS was not observed in all of the sections performed for immunohistochemistry, because of the focal and segmental features of the disease.


View this table:
[in this window]
[in a new window]

  		Table 2. Biopsy findings

 

View this table:
[in this window]
[in a new window]

  		Table 3. Immunohistochemistrya

 

Figure 3
View larger version (194K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 3. Histopathology. (A through C) Classical FSGS (or variant not otherwise specified) lesions in renal biopsies from patients in the de novo group. Note the podocyte hyperplasia (arrows) and detached floating podocytes (arrowhead). (D) Classical FSGS lesion in renal biopsy from a patient in the switched group showing scarring fibrosis with a clear halo (arrow). Masson’s trichrome stain in A, B, and D; periodic acid-Schiff stain in C. Magnifications: x700 in A through C; x400 in D.

 
In FSGS lesions, podocytes had lost synaptopodin and acquired new epitopes, cytokeratin and PAX2 (Figure 4). To a lesser extent, a decrease of p57 expression was observed in podocytes in some glomeruli. Staining for VEGF was lost in some FSGS lesions. VEGF expression was also studied in a patient who developed CNI-induced FSGS lesions. Although a strong VEGF signal was observed in normal glomeruli, unfortunately no FSGS lesions were present on immunohistochemistry sections (Figure 4).


Figure 4
View larger version (99K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 4. Immunohistochemistry on renal biopsies from the de novo group of patients. (A) Abnormal cytokeratin expression in hyperplastic visceral podocytes (arrows) in an FSGS lesion. (B) Abnormal PAX2 expression in hyperplastic visceral podocytes (arrows) in an FSGS lesion. (C) Focal loss of synaptopodin expression in an FSGS lesion (arrow). (D) Focal loss of VEGF expression in hyperplastic visceral podocytes in an FSGS lesion (arrows). (E) In an adjacent normal glomerulus on the same biopsy, the VEGF expression is normal. (F) Normal VEGF expression in a normal glomerulus on the biopsy from the tacrolimus-treated patient. (G) In a rejecting graft without FSGS, visceral podocytes do not express cytokeratin. (H) In a rejecting graft without FSGS, visceral podocytes do not express PAX2. Magnifications: x600 in A, B, and D; x400 in C, E, F, G, and H.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Conclusion
 Disclosures
 References
 
Since its first description at the Necker hospital in 2003 (1), many studies have reported an increase in proteinuria, sometimes of nephrotic range, after conversion from CNI to sirolimus (1–6,11,12). The main interest of this study is the first demonstration that renal transplant recipients who are treated by sirolimus de novo may develop FSGS lesions, distinct from collapsing glomerulopathy, suggesting a direct involvement of sirolimus itself. In addition, we identified specific markers of podocyte phenotypic dysregulation in these lesions (7,13–16).

Sirolimus-Induced Proteinuria and Glomerular Lesions
CNI withdrawal per se may unmask underlying glomerular damage that results in proteinuria. Ducloux et al. (17) reported that in 31 renal transplant recipients whose cyclosporine (CsA) was withdrawn because of cyclosporine toxicity or CAN, baseline proteinuria was 0.79 ± 0.6 g/d and increased to 1.79 ± 0.8 g/d 24 mo after CsA withdrawal. Because CNI reduce renal blood flow, CNI withdrawal may reveal existing CAN lesions that result in proteinuria, and an increase in intraglomerular pressure has been described after the switch (3,5,18).

Nevertheless, several lines of evidence argue for a specific role of sirolimus in the development of glomerular lesions. First, we previously observed a dramatic increase in urinary protein excretion and the existence of nephrotic-range proteinuria after the conversion from CNI to sirolimus in individual patients who had no significant proteinuria before (5). Conversion in stable renal transplant recipients (without evidence for renal lesions) is associated with the development of proteinuria in 30% of the patients (6).

Second, the kinetics of the increase in proteinuria raise questions: the incidence and the severity of proteinuria increase gradually from month 3 to months 12 to 24 after conversion, suggesting that a process is at work and that the acute increase in intraglomerular pressure at the time of the conversion does not totally explain the proteinuria (5). In a similar way, a progressive increase of proteinuria was observed in de novo patients in this study.

Third, cases of proteinuria and microalbuminuria in patients who were treated with sirolimus after clinical islet transplantation have been reported (19). Proteinuria and microalbuminuria resolved after both sirolimus discontinuation and simultaneous increase in tacrolimus dose, suggesting an effect of sirolimus itself on native kidneys in patients with diabetic. In a similar way, a recent report demonstrated that conversion from azathioprine to sirolimus in renal transplant patients may cause an increase of proteinuria that cannot be ascribed to hemodynamic renal effects of CNI withdrawal (20).

It has been recognized since 2003 that some patients develop FSGS after the switch (1). However, these data did not prove that sirolimus was involved, because all patients received CNI previously. It has been observed that 10% of patients who are on a CNI-based immunosuppressive regimen may develop progressive FSGS lesions and that CsA induces glomerular injury in cardiac transplant recipients (21,22). Nevertheless, "symptomatic" de novo FSGS lesions in renal transplantation have been essentially described in a context of de novo collapsing glomerulopathy (23). This rare case is characterized by nephrotic-range proteinuria and podocyte injury, but rapid decline in renal function and capillary collapse distinguish it from our cases. The development of FSGS in renal transplant recipients who never received CNI and did not have a medical history of FSGS lesions in native kidneys strongly support the hypothesis that sirolimus exerts a direct effect on podocytes. The exact prevalence of sirolimus-induced FSGS lesions is difficult to assess because borderline cases may be underscored, but an estimation of 3 or 4% at least seems likely in our units.

Evidence for FSGS and Podocyte Phenotypic Changes
Histologic analyses showed that the first detectable lesions are the cellular type of FSGS and that scar formation and tuft contraction follow (24). It was previously demonstrated that podocyte phenotypic changes accompany or follow the podocyte injury that is observed in recurrent FSGS in renal transplant recipients (7). The origin of these cells remains controversial, however (25,26). Similar to the initial lesions that are observed in recurrence of primary FSGS, here we observed few scar lesions and focal changes in podocyte phenotype, suggesting podocyte dedifferentiation because synaptopodin expression was lost and a fetal phenotype pattern developed, with podocyte expression of cytokeratin and PAX2 in some FSGS cellular lesions. We previously observed exactly the same pattern in recurrent FSGS and showed that adult podocytes in control biopsies do not express PAX2 and cytokeratin but are labeled by synaptopodin mAb (7). The small sample size and the lack of sections with FSGS lesions are a limitation of the study, but, in our experience, this pattern is specific of phenotype dysregulation.

Potential Mechanisms of Sirolimus-Induced Toxicity
A recent article noted no podocytes foot process effacement and the absence of albumin tubular reabsorption in a case of sirolimus-associated proteinuria, suggesting that tubular injury explains proteinuria (27). Nevertheless, the present study provides evidence for podocyte injury, and the existence of a nephrotic-range proteinuria suggests that a glomerular mechanism is involved. Further studies may assess the respective participation of tubular and glomerular mechanism in the development of proteinuria.

Sirolimus is known to decrease VEGF synthesis, making it an interesting drug for transplant patients who develop Kaposi or malignant diseases (28). Moreover, in a recent case report of sirolimus-induced thrombotic microangiopathy, a decreased expression of VEGF in glomeruli seemed to be the consequence of sirolimus treatment (29). Experimental data suggest that podocytes have a functional autocrine VEGF-A system that promotes podocyte survival and differentiation (30). It is interesting that we found a focal decrease of VEGF expression in podocytes in FSGS lesions. By comparison, we observed an intense expression of VEGF in podocytes of a tacrolimus-treated patient who developed FSGS lesions. Unfortunately, no typical lesions of FSGS but only abnormally enlarged podocytes were seen on VEGF-stained sections in this patient. Therefore, it cannot be determined whether sirolimus causes VEGF decrease or this decrease is a consequence of podocyte dedifferentiation. Our data contrast with those of a recent report that described a collapsing glomerulopathy associated with an increased expression of VEGF in glomeruli in a renal transplant recipient who converted to sirolimus because of an human herpesvirus 8–related Kaposi (31). These lesions were attributed to sirolimus. Collapsing glomerulopathy is the classic lesion seen in HIV-associated nephropathy and is experimentally induced when podocyte-specific overexpression of the VEGF164 isoform is promoted (32). Because we observed a clearly different variant of FSGS lesions and because sirolimus does not increase VEGF synthesis but rather decreases it, the responsibility of sirolimus seems doubtful in this observation.

Beyond its role in VEGF synthesis, sirolimus blocks mammalian target of rapamycin (mTOR) activity, which itself regulates Akt, an essential pathway for cell survival, differentiation, and adhesion. It was recently shown that prolonged sirolimus treatment reduces mTORC2, a multiprotein complex that contains mTOR, to levels below those needed to maintain Akt signaling (33). Moreover, recent reports emphasized the role of integrin-linked kinase, an activator of the Akt pathway, in podocyte survival and cytoskeleton maintenance (34).

Because residual concentrations of sirolimus were higher than those currently recommended, sirolimus may have exerted direct toxicity on podocytes. Nevertheless, many patients were exposed to similar concentrations of sirolimus until 2003 and did not develop nephrotic-range proteinuria or FSGS lesions. In the same way, we did not find any correlation between sirolimus levels and urinary protein excretion level (personal data).

It seems likely that FSGS lesions occur only in particularly susceptible patients, but we did not identify any demographic factor that could explain this point. Similarly, sirolimus enhances ischemia-reperfusion injury in renal tubular cells but does not alter renal function in stable renal transplant recipients (35). The underlying mechanisms of this individual susceptibility are unknown. Renal biopsies that were performed on the day of transplantation in patients 1 to 3 did not show significant lesions. Donors were young. Patients did not receive CNI or have hypertension. There was no acute vascular rejection, but the rapid development of vascular lesions and especially arteriolar hyalinosis in the de novo group is noteworthy. Similar processes might underlie glomerular and vascular lesions.


   Conclusion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
Disclosures
 References
 
Predisposed patients may develop FSGS lesions and nephrotic syndrome when exposed to high concentrations of sirolimus. Close monitoring of urinary protein excretion and the search for podocyte injury in renal biopsy should be recommended in patients who receive sirolimus, either de novo or after conversion from CNI. Beyond their clinical impact, sirolimus-induced FSGS lesions may offer insights into the importance of VEGF autocrine and paracrine effects and mTOR signaling in maintenance of human podocyte differentiation.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 Disclosures
References
 
None.


   Acknowledgments
 
We thank Dr. G.S. Hill for useful comments on the text.


   Footnotes
 
Published online ahead of print. Publication date available at www.cjasn.org.

See the related editorial, "Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient," on pages 198–199.

Received November 13, 2006. Accepted December 26, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 Disclosures
 References
 

  1. Morelon E, Kreis H: Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc35[Suppl] :52S –57S,2003[CrossRef][Medline]
  2. Butani L: Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation78 :1362 –1366,2004[CrossRef][Medline]
  3. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM: Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant4 :1869 –1875,2004[CrossRef][Medline]
  4. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant20 :2517 –2523,2005[Abstract/Free Full Text]
  5. Letavernier E, Peraldi MN, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation80 :1198 –1203,2005[CrossRef][Medline]
  6. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA: Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation80 :1578 –1585,2005[CrossRef][Medline]
  7. Bariety J, Bruneval P, Hill G, Irinopoulou T, Mandet C, Meyrier A: Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation. J Am Soc Nephrol12 :261 –274,2001[Abstract/Free Full Text]
  8. Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C: Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int68 :1109 –1119,2005[CrossRef][Medline]
  9. D’Agati V: Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol23 :117 –134,2003[CrossRef][Medline]
  10. D’Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis43 :368 –382,2004[CrossRef][Medline]
  11. Skhiri H, Morelon E, Noel LH, Mamzer-Bruneel MF, Legendre C, Peraldi MN, Kreis H: Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transpl Int18 :458 –460,2005[CrossRef][Medline]
  12. Boratynska M, Banasik M, Watorek E, Falkiewicz K, Patrzalek D, Szyber P, Klinger M: Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc38 :101 –104,2006[CrossRef][Medline]
  13. Barisoni L, Mundel P: Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol23 :353 –360,2003[CrossRef][Medline]
  14. Barisoni L, Kriz W, Mundel P, D’Agati V: The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol10 :51 –61,1999[Abstract/Free Full Text]
  15. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A: Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int53 :918 –925,1998[CrossRef][Medline]
  16. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int58 :137 –143,2000[CrossRef][Medline]
  17. Ducloux D, Motte G, Billerey C, Bresson-Vautrin C, Vautrin P, Rebibou JM, Saint-Hillier Y, Chalopin JM: Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: A 2-year follow-up. Transpl Int15 :387 –392,2002[CrossRef][Medline]
  18. Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant21 :488 –493,2006[Abstract/Free Full Text]
  19. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant5 :2318 –2323,2005[CrossRef][Medline]
  20. van den Akker JM, Wetzels JF, Hoitsma AJ: Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int70 :1355 –1357,2006[CrossRef][Medline]
  21. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, et al.: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int33 :590 –600,1988[Medline]
  22. Takeda A, Uchida K, Haba T, Tominaga Y, Katayama A, Yoshida A, Oikawa T, Morozumi K: Chronic cyclosporin nephropathy: Long-term effects of cyclosporin on renal allografts. Clin Transplant15[Suppl 5] :22 –29,2001
  23. Meehan SM, Pascual M, Williams WW, Tolkoff-Rubin N, Delmonico FL, Cosimi AB, Colvin RB: De novo collapsing glomerulopathy in renal allografts. Transplantation65 :1192 –1197,1998[CrossRef][Medline]
  24. Korbet SM, Schwartz MM, Lewis EJ: Recurrent nephrotic syndrome in renal allografts. Am J Kidney Dis11 :270 –276,1988
  25. Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J: The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int68 :1562 –1572,2005[CrossRef][Medline]
  26. Bariety J, Bruneval P: Activated parietal epithelial cells or dedifferentiated podocytes in FSGS: Can we make the difference? Kidney Int69 :194 ,2006[Medline]
  27. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB: Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant6 :429 –433,2006[CrossRef][Medline]
  28. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med352 :1317 –1323,2005[Abstract/Free Full Text]
  29. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P: Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant5 :2441 –2447,2005[CrossRef][Medline]
  30. Guan F, Villegas G, Teichman J, Mundel P, Tufro A: Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol291 :F422 –F428,2006[Abstract/Free Full Text]
  31. Izzedine H, Brocheriou I, Frances C: Post-transplantation proteinuria and sirolimus. N Engl J Med353 :2088 –2089,2005[Free Full Text]
  32. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest111 :707 –716,2003[CrossRef][Medline]
  33. Sarbassov dos D, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell22 :159 –168,2006[CrossRef][Medline]
  34. El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi MP, Jarad G, Miner JH, Moeller MJ, St-Arnaud R, Dedhar S, Holzman LB, Wanke R, Kretzler M: Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol17 :1334 –1344,2006[Abstract/Free Full Text]
  35. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol281 :F693 –F706,2001[Abstract/Free Full Text]

Related Article

Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient
Stephen J. Tomlanovich and Flavio Vincenti
Clin. J. Am. Soc. Nephrol. 2007 2: 198-199. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Torras, I. Herrero-Fresneda, O. Gulias, M. Flaquer, A. Vidal, J. M. Cruzado, N. Lloberas, M.{m. d.}l. Franquesa, and J. M. Grinyo
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
Nephrol. Dial. Transplant., August 11, 2009; (2009) gfp367v1.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. S. Gipson, S. F. Massengill, L. Yao, S. Nagaraj, W. E. Smoyer, J. D. Mahan, D. Wigfall, P. Miles, L. Powell, J.-J. Lin, et al.
Management of Childhood Onset Nephrotic Syndrome
Pediatrics, August 1, 2009; 124(2): 747 - 757.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. A. Perazella
Renal Vulnerability to Drug Toxicity
Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1275 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R John and A M Herzenberg
Renal toxicity of therapeutic drugs
J. Clin. Pathol., June 1, 2009; 62(6): 505 - 515.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. Chailimpamontree, S. Dmitrienko, G. Li, R. Balshaw, A. Magil, R. J. Shapiro, D. Landsberg, J. Gill, P. A. Keown, and and the Genome Canada Biomarkers in Transplantatio
Probability, Predictors, and Prognosis of Posttransplantation Glomerulonephritis
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 843 - 851.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M.-F. Belair, J.-p. Haymann, C. Legendre, and L. Baud
Sirolimus interacts with pathways essential for podocyte integrity
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 630 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Skoberne, A. Konieczny, and M. Schiffer
Glomerular epithelial cells in the urine: what has to be done to make them worthwhile?
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F230 - F241.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
B. Vollenbroker, B. George, M. Wolfgart, M. A. Saleem, H. Pavenstadt, and T. Weide
mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F418 - F426.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
W. A. Golgert, G. B. Appel, and S. Hariharan
Recurrent Glomerulonephritis after Renal Transplantation: An Unsolved Problem
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
M. Nepal, R. Mainali, C. M. Schworer, W. Difilippo, P. L. Zhang, and M. F. Schultz
Nephrotic Range Proteinuria: Rare Manifestation of Scleroderma Renal Crisis
Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 163 - 167.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.03751106v1
2/2/326    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letavernier, E.
Right arrow Articles by Legendre, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letavernier, E.
Right arrow Articles by Legendre, C.
Related Collections
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS